BIOMAT Database Logo BIOMAT Database Logo

Intensive chemotherapy of acute myelogenous leukaemia. 1972

A Gorman, and J J Fennelly, and L G O'Connell

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A Gorman, and J J Fennelly, and L G O'Connell
Chemotherapy of acute myelogenous leukaemia.
January 1991, Bailliere's clinical haematology,
A Gorman, and J J Fennelly, and L G O'Connell
Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy.
October 1994, British journal of haematology,
A Gorman, and J J Fennelly, and L G O'Connell
Intensive chemotherapy for acute myelogenous leukemia.
June 1981, Annals of internal medicine,
A Gorman, and J J Fennelly, and L G O'Connell
Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
December 1989, Bone marrow transplantation,
A Gorman, and J J Fennelly, and L G O'Connell
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
November 1992, Journal of internal medicine,
A Gorman, and J J Fennelly, and L G O'Connell
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
April 1984, Lancet (London, England),
A Gorman, and J J Fennelly, and L G O'Connell
Acute myelogenous leukaemia.
February 1998, Critical reviews in oncology/hematology,
A Gorman, and J J Fennelly, and L G O'Connell
Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?
November 2001, Expert opinion on biological therapy,
A Gorman, and J J Fennelly, and L G O'Connell
Intensive sequential chemotherapy for children with acute myelogenous leukemia.
January 1990, Haematology and blood transfusion,
A Gorman, and J J Fennelly, and L G O'Connell
Hypoplastic acute myelogenous leukaemia.
October 1975, British journal of haematology,
Copied contents to your clipboard!